Germany · Delayed Price · Currency is EUR FamiCord AG Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and EBITDA improved year-over-year, driven by recurring payments and new CDMO contracts. Settled Cryo-Save litigation opens new revenue opportunities, while the placenta business in Germany is set to launch in Q3 next year. M&A activity is limited by capital constraints.
-
Leading European stem cell bank projects strong 2024 growth, with revenue guidance of €85–95 million and EBITDA of €8.7–10.3 million. Market share exceeds 55% in Europe, with expansion focused on new products and geographies. Placenta banking rollout continues, with regulatory delays in Germany but imminent launch in Portugal.
-
Stem cell banking penetration in Europe remains low but is recovering, with strong growth in Eastern Europe and new product rollouts like placenta banking. Guidance is realistic, with further EBITDA gains expected from acquisitions and a shift in focus to core operations.